Virax Biolabs Group Statistics
Total Valuation
VRAX has a market cap or net worth of $1.91 million. The enterprise value is -$4.20 million.
| Market Cap | 1.91M |
| Enterprise Value | -4.20M |
Important Dates
The next estimated earnings date is Friday, November 20, 2026.
| Earnings Date | Nov 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VRAX has 796,988 shares outstanding. The number of shares has increased by 166.46% in one year.
| Current Share Class | 796,988 |
| Shares Outstanding | 796,988 |
| Shares Change (YoY) | +166.46% |
| Shares Change (QoQ) | +217.37% |
| Owned by Insiders (%) | 3.64% |
| Owned by Institutions (%) | 3.31% |
| Float | 727,944 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 153.65 |
| Forward PS | n/a |
| PB Ratio | 0.18 |
| P/TBV Ratio | 0.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.97, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.97 |
| Quick Ratio | 9.55 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -103.60 |
Financial Efficiency
Return on equity (ROE) is -78.65% and return on invested capital (ROIC) is -58.87%.
| Return on Equity (ROE) | -78.65% |
| Return on Assets (ROA) | -54.23% |
| Return on Invested Capital (ROIC) | -58.87% |
| Return on Capital Employed (ROCE) | -83.77% |
| Weighted Average Cost of Capital (WACC) | 11.71% |
| Revenue Per Employee | $478 |
| Profits Per Employee | -$193,221 |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.04 |
Taxes
| Income Tax | -900,240 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.97% in the last 52 weeks. The beta is 1.35, so VRAX's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -84.97% |
| 50-Day Moving Average | 2.87 |
| 200-Day Moving Average | 4.90 |
| Relative Strength Index (RSI) | 40.51 |
| Average Volume (20 Days) | 33,593 |
Short Selling Information
The latest short interest is 30,516, so 3.83% of the outstanding shares have been sold short.
| Short Interest | 30,516 |
| Short Previous Month | 19,982 |
| Short % of Shares Out | 3.83% |
| Short % of Float | 4.19% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, VRAX had revenue of $12,423 and -$5.02 million in losses. Loss per share was -$12.64.
| Revenue | 12,423 |
| Gross Profit | 7,690 |
| Operating Income | -6.40M |
| Pretax Income | -5.93M |
| Net Income | -5.02M |
| EBITDA | -6.05M |
| EBIT | -6.40M |
| Loss Per Share | -$12.64 |
Balance Sheet
The company has $6.52 million in cash and $414,387 in debt, with a net cash position of $6.10 million or $7.66 per share.
| Cash & Cash Equivalents | 6.52M |
| Total Debt | 414,387 |
| Net Cash | 6.10M |
| Net Cash Per Share | $7.66 |
| Equity (Book Value) | 7.33M |
| Book Value Per Share | 13.08 |
| Working Capital | 6.14M |
Cash Flow
In the last 12 months, operating cash flow was -$4.62 million and capital expenditures -$255,831, giving a free cash flow of -$4.88 million.
| Operating Cash Flow | -4.62M |
| Capital Expenditures | -255,831 |
| Depreciation & Amortization | 351,581 |
| Net Borrowing | 4.30M |
| Free Cash Flow | -4.88M |
| FCF Per Share | -$6.12 |
Margins
| Gross Margin | 61.90% |
| Operating Margin | -51,515.17% |
| Pretax Margin | -47,753.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VRAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -166.46% |
| Shareholder Yield | -166.46% |
| Earnings Yield | -263.19% |
| FCF Yield | -255.54% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 26, 2026. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jun 26, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
VRAX has an Altman Z-Score of -4.82 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.82 |
| Piotroski F-Score | 4 |